Articles On Paradigm Biopharmaceuticals (ASX:PAR)

Who said free-to-air TV was in its death throes? When the Seven news network ran a piece about Paradigm Biopharmaceuticals’ (ASX:PAR) knee osteoarthritis (OA) drug candidate a few months ago, the company received around 700 emails from suff...

Paradigm Biopharma (ASX:PAR) has engaged a Scandinavian entity called Nordic Bioscience Clinical Development (NBCD) to expand the scope of its Phase 3 trial using its flagship product to treat osteoarthritis (OA) in knee joints. Listen...

ASX healthcare sector fell 4.83% in October and is down more than 19% YTD CSL shares fall more than 15% on October 28 after management trims FY26 guidance Nyrada surges 165% in October on board changes and progress in phase 2a trial    Wi...

Biotechs are adopting ‘plan B’ strategies by purchasing complementary drug programs Antivirals house Biotron hopes to shake up the moribund anaesthetic drug sector Other companies with interesting diversions include Island Pharmaceuticals,...

It’s a fairly common occurrence for ASX-listed companies to start slowing down their operations as the holiday season draws near – but not so for Paradigm Pharmaceuticals (ASX:PAR), which only just last week both successfully recruited and...

If you have a high tolerance for risk, then it could be worth checking out the ASX stock in this article. That's because analysts at Bell Potter believe that its shares could rise materially over the next 12 months. Which ASX stock? The sto...

Pfizer has become the first Big Pharma company to sign a pricing deal with the Trump administration Bioxyne has the dope on likely US medical pot reforms Paradigm trial gets a knees-up with its first patient dosed The Trump administration...

On Tuesday, the S&P/ASX 200 Index (ASX: XJO) fought hard but ended the session in the red. The benchmark index fell 0.15% to 8,848.8 points. Will the market be able to bounce back from this on Wednesday? Here are five things to watch:...

Paradigm Biopharma (ASX:PAR) has officially kicked off its final-stage Phase 3 trial using injectable pentosan polysulfate sodium (iPPS) to treat patients with osteoarthritis (OA) in their knee joints, with randomised participants having no...

After a strategy revamp, Noxopharm is targeting inflammatory diseases – lupus in particular Affecting five million people, lupus has proved a tricky disease to tackle The company is pondering a phase II trial, most likely in skin lupus No...

Paradigm Pharmaceuticals (ASX:PAR) has been the clear winner on the HotCopper forums today after securing US$27 million in funding. (For a little more detail there, read my colleague Jonathon Davidson’s full write-up.) Listen to the HotC...

Highlights Bioxyne outpaces sector peers with performance in cannabis and health products Paradigm Biopharmaceuticals secures convertible note funding for late-stage trial Recce Pharmaceuticals and Botanix turn to debt as eq...

Bioxyne stars with a 720% gain in the 2024-25 year Paradigm shares soar 34% after $41 million convertible note deal Biotechs turn to debt funding The ASX biotech sector’s best EOFY performer has come from left field: the local and Europ...

Paradigm Biopharmaceuticals (ASX:PAR) shares were up nearly +25% in morning trades as the company unveiled a loan of around $41 million to advance its osteoarthritis clinical investigations. Listen to the HotCopper podcast for in-depth d...

Paradigm Biopharmaceutical (ASX: PAR) has opened the purse strings to pick up Proteobioactives Pty Ltd, which has been working on Pentacoxib, an early-stage oral candidate for minor to mild osteoarthritis. Listen to the HotCopper podcast...

The ASX200 traded flat yet again today, closely mimicking Wall Street. IT was heavily sold off in intra-day trade, followed by Real Estate and Industrials. Health Care and Financials were the only sectors substantially in the green. I...

Late-stage drug developer Paradigm (ASX:PAR) is trending today after adding a new oral combination IP to its osteoarthritis drug stable. The acquisition came after the company paid $500,000 to buy up Proteobioactives. Listen to the HotCo...

Paradigm Biopharmaceuticals will spend up to $16.5 million on an oral drug asset, but stays focused on its phase III knee trial Percheron enters headline $450 million cancer drug acquisition Neurizon goes from solid to liquid with its moto...

The S&P/ASX 200 Index (ASX: XJO) is out of form on Thursday and trading lower. At the time of writing, the benchmark index is down 0.2% to 8,540.7 points. Four ASX shares that are not letting that hold them back are listed below. Here's...

Paradigm Biopharmaceuticals (ASX:PAR) has acquired the exclusive global rights to develop – and, of course, commercialise – a novel oral combination of PPS and a COX-2 inhibitor designed to treat osteoarthritis and pains. Listen to the...

The market may be having a subdued start to the day but that hasn't stopped two ASX healthcare stocks from racing higher. Let's see why investors are bidding them higher today: Neuren Pharmaceuticals Ltd (ASX: NEU) The Neuren share price i...

The S&P/ASX 200 Health Care Index rose 1.59% in May but remains worst performing sector YTD down 5.65% Morgans healthcare analyst Iain Wilkie said US President Donald Trump’s trade and health policies continue to impact sector Lumos up...

Paradigm Biopharmaceuticals (ASX:PAR) has activated its first Australian clinical site as part of a Phase Three trial to assess injectable pentosan polysulfate sodium for the treatment of pain connected to knee osteoarthritis. Listen to...

Paradigm Biopharmaceuticals (ASX:PAR) is a late-stage drug development company working first and foremost to create a superior treatment for osteoarthritis. In the background, Paradigm also has a rare disease clinal asset for Mucopolysac...

Amplia says it has reached the requisite level of ‘partial responders’ in its mid-stage pancreatic cancer study Immutep reports “remarkable” response rates in a German-based lung cancer trial Paradigm wins US ethics approval for knee osteo...

Despite a late upturn, the ASX 200 closed 0.38% in the red on Thursday Blame factor 1: Trump and his 25% US auto import tariffs, set to come into play early April Blame factor 2: A Wall Street tech rout, which Trump had a hand in, too   ...

A cabal of ASX drug developers has defied the US gloom The healthcare jury’s out on new FDA head Dr Marty Makary Emvision’s Emu trial takes flight Amid the downbeat narrative about US healthcare policy and cuts to funding agencies, a ‘Mag...

Telix expects three more US product approvals this year Patrys switches to plan B Biotron’s do-or-die $500,000 capital raising   Analysts reckon Telix Pharmaceuticals (ASX:TLX) has only just started to reach its full potential, with three...

  Emyria says its ‘real world’ MDMA trial shows a “sustained improvement” in post-traumatic stress disorder (PTSD) symptoms Argenica says its traumatic brain injury candidate works in rats – and ferrets The biotech sector advanced to recor...

The S&P/ASX 200 rose 5% in January to reach a new record high Utilities was the only sector to fall in January with financials the top performer AusQuest tops January winners up 388% with discovery of a large-scale Peruvian copper pros...

  Paradigm launches loyalty options and piggyback options offer to reward shareholders for support Offer has potential to raise more than $110 million for the company Paradigm set to start phase III trial of PARA_OA_012 to treat knee OA in...

Dimerix forecasting second interim analysis of its ACTION3 phase III trial mid CY25 Retinal-diseases-focused biotech Opthea is awaiting two trial results in CY25 Recce set to start trial assessing topical gel to treat diabetic foot infecti...

ASX edges up as Trump stirs markets Wesfarmers jumps, oil stocks slide after Trump Davos speech BoJ hikes rates, Yen fluctuates   The ASX crept up 0.3% on Friday and for the week the S&P/ASX 200 benchmark was up over 1%.  Overnight, T...

ASX healthcare stocks are in the green on Friday, with the S&P/ASX 200 Health Care Index (ASX: XHJ) 0.41% higher while the benchmark S&P/ASX 200 Index (ASX: XJO) is up 0.32%. Here are three of the best-performing ASX healthcare s...

Surgical probe steriliser Nanosonics flags robust December half numbers The biotech quarterlies are tricking in – and there’s mixed news Paradigm shares are worth twice as much as their current price, says Pitt Street Partners   Nanosonic...

Investors with a high risk tolerance may want to take a look at the small cap ASX shares in this article. That's because they have just been named as buys and tipped to rise materially from current levels. Here's what analysts are saying ab...

S&P/ASX All Ords (ASX: XAO) shares fell 3.2% in December in an unusually weak final month of the year. Meantime, some brokers changed their ratings on various ASX stocks before heading off on holidays. Here are six ASX All Ords sh...

Sonic Healthcare to buy LADR – Laboratory Group Dr. Kramer & Colleagues in Germany for ~A$700 million ASX health stocks fall 2.3% over past five days, while the broader market fell ~1.5%  Chemist Warehouse could list on the ASX by earl...

Opyl has partnered to form the ‘world’s first’ AI-driven biotech fund Visioneering sees a brighter future – elsewhere – but its shares tumble  Cyclopharm breathes easy after decent lung transplant trial results   Who needs fund managers t...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a small decline. At the time of writing, the benchmark index is down almost 0.2% to 8,407 points. Four ASX shares that are falling more than most today are lis...

Paradigm Biopharmaceuticals Ltd (ASX: PAR) shares are starting the week deep in the red. In morning trade, the ASX healthcare stock is down 26% to 43 cents. Why is this ASX healthcare stock crashing deep into the red? The catalyst for today...

Investors that have a high tolerance for risk might want to consider the small cap ASX shares in this article. That's because they have just been named as buys with major upside potential. Here's what analysts are saying about them: Ai-Med...

ASX healthcare stock Paradigm Biopharmaceuticals Ltd (ASX: PAR) has been on a strong run in the past month, soaring 160%. But the drug development company has requested a pause in the trading of its shares before the open on Thursday....

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

The S&P/ASX 200 rose 4% in November to a new record high of 8436.23 points as volatility fell following US election Information Technology led the gainers rising 10% in November and remained top performer YTD, up 56.79%  NoviqTech rose...

If you have a high tolerance for risk, then read on! That's because the two small cap ASX shares listed below have just been named as buys and tipped to rise strongly from current levels. Here's what brokers are saying about these shares:...

This week’s Bulls N’ Bears Runner of the Week is … PhosCo. The African phosphate explorer nabbed a vital exploration permit, while Paradigm Biopharmaceuticals, AV Jennings and Errawarra Resources also ran hard.

Good afternoon, a happy end of the week, and welcome to HotCopper Highlights – I’m Jonathon Davidson.  Let’s get into it. Perth Basin gas developer Strike Energy commanded 13, 205 eyes on Thursday with its news the company will go ahe...

ASX hits new record high, driven by banks and health stocks Pro Medicus signs $330m deal with Trinity Health Lithium stocks rise on WA government’s $150m support package   The ASX touched a new record high on Thursday, the second time thi...

US FDA successfully concludes 30-day review of Paradigm Biopharmaceuticals phase III trial protocol Pivotal trial of repurposed pentosan polysulfate sodium (Zilosul) to treat knee osteoarthritis due to start in Q1 CY25 Paradigm to progress...